Quantbot Technologies LP bought a new stake in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 7,158 shares of the specialty pharmaceutical company’s stock, valued at approximately $172,000.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Vanguard Group Inc. raised its position in shares of Paratek Pharmaceuticals by 19.8% in the second quarter. Vanguard Group Inc. now owns 867,616 shares of the specialty pharmaceutical company’s stock valued at $20,909,000 after buying an additional 143,316 shares during the last quarter. Northern Trust Corp raised its position in shares of Paratek Pharmaceuticals by 25.9% in the second quarter. Northern Trust Corp now owns 329,693 shares of the specialty pharmaceutical company’s stock valued at $7,946,000 after buying an additional 67,794 shares during the last quarter. Citigroup Inc. raised its position in shares of Paratek Pharmaceuticals by 19,470.0% in the second quarter. Citigroup Inc. now owns 7,828 shares of the specialty pharmaceutical company’s stock valued at $189,000 after buying an additional 7,788 shares during the last quarter. Nicholas Investment Partners LP raised its position in shares of Paratek Pharmaceuticals by 573.5% in the second quarter. Nicholas Investment Partners LP now owns 204,009 shares of the specialty pharmaceutical company’s stock valued at $4,916,000 after buying an additional 173,717 shares during the last quarter. Finally, New York State Common Retirement Fund raised its position in shares of Paratek Pharmaceuticals by 19.7% in the second quarter. New York State Common Retirement Fund now owns 39,399 shares of the specialty pharmaceutical company’s stock valued at $950,000 after buying an additional 6,491 shares during the last quarter. Institutional investors and hedge funds own 82.37% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “7,158 Shares in Paratek Pharmaceuticals, Inc. (PRTK) Purchased by Quantbot Technologies LP” was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another domain, it was copied illegally and reposted in violation of US and international copyright legislation. The original version of this news story can be viewed at https://www.watchlistnews.com/7158-shares-in-paratek-pharmaceuticals-inc-prtk-purchased-by-quantbot-technologies-lp/1614827.html.

Shares of Paratek Pharmaceuticals, Inc. (NASDAQ PRTK) opened at 25.40 on Friday. Paratek Pharmaceuticals, Inc. has a 52-week low of $9.80 and a 52-week high of $29.00. The firm’s market capitalization is $705.13 million. The company’s 50-day moving average is $25.04 and its 200 day moving average is $22.43.

Paratek Pharmaceuticals (NASDAQ:PRTK) last released its earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported ($0.64) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.89) by $0.25. The firm had revenue of $7.51 million during the quarter, compared to analysts’ expectations of $7.50 million.

Several equities research analysts recently issued reports on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $50.00 price objective on shares of Paratek Pharmaceuticals in a research report on Thursday, June 22nd. BidaskClub cut shares of Paratek Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, August 23rd. Zacks Investment Research cut shares of Paratek Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, August 8th. HC Wainwright raised their price objective on shares of Paratek Pharmaceuticals from $36.00 to $43.00 and gave the stock a “buy” rating in a research report on Tuesday, July 18th. Finally, ValuEngine cut shares of Paratek Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, September 18th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $37.44.

About Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.

Want to see what other hedge funds are holding PRTK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK).

Institutional Ownership by Quarter for Paratek Pharmaceuticals (NASDAQ:PRTK)

Receive News & Ratings for Paratek Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.